PAVmed Inc.
For the period ended Dec 31, 2024. Filed Mar 24, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 24, 2025
PAVM$1.56-4.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity (Deficit)
CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)
for the YEAR ENDED December 31, 2024
| PAVmed Inc. Stockholders’ Equity (Deficit) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Series B Convertible Preferred Stock · Common Stock · Additional Paid-In · Accumulated · Non controlling | |||||||||
| Shares · Amount · Shares · Amount · Capital · Deficit · Interest · Total | |||||||||
| Balance - December 31, 2023 | 1,305,213 | $2,993 | 8,578,505 | $9 | $237,600 | $(294,433) | - | $29,813 | $(24,018) |
| Dividends declared - Series B Convertible Preferred Stock | 107,652 | 323 | — | — | — | (323) | - | — | — |
| Issue common stock - PAVM ATM Facility | — | — | 1,032,298 | 1 | 1,307 | — | - | — | 1,308 |
| Vest - restricted stock awards | — | — | 136,096 | — | — | — | - | — | — |
| Conversions - Senior Secured Convertible Note | — | — | 1,084,366 | 1 | 2,019 | — | - | — | 2,020 |
| Conversions - subsidiary common stock - Senior Secured Convertible Note | — | — | — | — | — | — | - | 3,801 | 3,801 |
| Exercise - stock options of subsidiary | — | — | — | — | — | — | - | 4 | 4 |
| Purchase - Employee Stock Purchase Plan | — | — | 34,332 | — | 62 | — | - | — | 62 |
| Purchase - subsidiary common stock - Employee Stock Purchase Plan | — | — | — | — | — | — | - | 353 | 353 |
| Impact of subsidiary equity transactions | — | — | — | — | 4,414 | — | - | (4,414) | — |
| Issuance - vendor service agreement | — | — | 333,380 | — | 350 | — | - | 401 | 751 |
| Issuance - subsidiary preferred stock (Series A-1) | — | — | — | — | — | — | - | 5,670 | 5,670 |
| Exchange - subsidiary preferred stock (Series A and Series A-1) | — | — | — | — | — | — | - | (24,294) | (24,294) |
| Issuance through exchange - subsidiary preferred stock (Series B and Series B-1) | — | — | — | — | — | — | - | 31,790 | 31,790 |
| Issuance through sale - subsidiary preferred stock (Series B and Series B-1) | — | — | — | — | — | — | - | 24,129 | 24,129 |
| Subsidiary deemed dividends on preferred stock attributable to noncontrolling interests | — | — | — | — | — | — | - | (7,496) | (7,496) |
| Stock-based compensation - PAVmed Inc. | — | — | — | — | 2,681 | — | - | — | 2,681 |
| Stock-based compensation - subsidiaries | — | — | — | — | 360 | — | - | 3,408 | 3,768 |
| Transfer of intellectual property to Lucid Diagnostics Inc | — | — | — | — | 350 | — | - | — | 350 |
| Deconsolidation of subsidiary | — | — | — | — | — | — | - | (56,339) | (56,339) |
| Net income (loss) | — | — | — | — | — | 39,791 | - | (11,364) | 28,427 |
| Balance - December 31, 2024 | 1,412,865 | $3,316 | 11,198,977 | $11 | $249,143 | $(254,965) | - | $(4,538) | $(7,033) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.